Cardiol Therapeutics Inc. (@CardiolRx) / X

Cardiol Therapeutics Inc.

751 posts

Cardiol Therapeutics Inc.

@CardiolRx

Late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease NASDAQ $CRDL TSX $CRDL

Toronto, Ontario

Joined May 2017

Cardiol Therapeutics Inc.
@CardiolRx
Jun 18
We're building toward multiple high-impact milestones — all tied to one mission: treating inflammation in heart disease. Pivotal Phase III MAVERIC topline data. CRD-38 IND submission. Rare disease expansion. Strategic partnerships. The key catalysts are lined up. $CRDL
330
Cardiol Therapeutics Inc.
@CardiolRx
Jun 17
Inflammation doesn't stop when symptoms do — and the structural consequences show up in the data. In our ARCHER trial, CardiolRx™ reduced left ventricular (LV) mass by 9.2 grams in patients with acute myocarditis — comparable to reductions seen with widely prescribed therapies
3.2K
Cardiol Therapeutics Inc.
@CardiolRx
Jun 9
A person with recurrent pericarditis knows the feeling. The pain subsides. Life starts to normalize. And then, weeks or months later, it comes back. That cycle of recurrence is one of the most difficult aspects of the disease. Treatments that provide short-term relief matter.
2.2K
Cardiol Therapeutics Inc.
@CardiolRx
Jun 4
From approximately six episodes per year to less than one. CEO David Elsley discusses the Phase II MAvERIC findings in recurrent pericarditis, and how those data helped form the basis for the now-enrolling pivotal Phase III MAVERIC trial. $CRDL
00:00
2.1K
Cardiol Therapeutics Inc.
@CardiolRx
May 26
Cardiol's President/CEO David Elsley sat down with Stocks to Watch to discuss our approach to targeting inflammation in heart disease — and what's ahead for $CRDL. 🎥 Watch the full interview: youtube.com/watch?v=NXkzgf… #HeartDisease #Biotech #CRDL #Pericarditis #Inflammation
12K
Cardiol Therapeutics Inc.
@CardiolRx
May 20
REPLAY: President/CEO David Elsley & CMO/Head of R&D Andrew Hamer joined @HCWCO yesterday in a Fireside Chat hosted by Brandon Folkes to discuss the pivotal Phase III MAVERIC trial, key value-driving milestones, and development of CRD-38. 🔗 Watch here: journey.ct.events/view/8d043006-…
6.9K
Cardiol Therapeutics Inc.
@CardiolRx
May 19
REMINDER: Cardiol Therapeutics will be presenting a Fireside Chat today at 1:30 p.m. ET at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the Nasdaq in New York City. $CRDL 📺Watch our Fireside Chat live via webcast — register here: journey.ct.events/view/8d043006-…
4.9K
Cardiol Therapeutics Inc.
@CardiolRx
May 14
We're pleased to share that Cardiol Therapeutics will participate in a Fireside Chat at the @HCWCO 4th Annual BioConnect Investor Conference, hosted at the @Nasdaq in New York City. Tune in on May 19 at 1:30 p.m. ET via live webcast. A replay will be available for 90 days.
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect...
From cardiolrx.com
4.7K
Cardiol Therapeutics Inc.
@CardiolRx
May 11
We’re proud to support @PericarditisA 1st Annual Platypus Run on May 16, 2026! The event helps raise awareness of pericarditis and brings together patients, families, and supporters through a 5K run, 1-mile walk, and virtual participation option. We’re pleased to stand with The
Pericarditis Alliance
@PericarditisA
May 11
The Platypus Run is almost here! If you’re joining us in Albuquerque, we’ll see you Saturday, May 16 at 8:30am MDT. Participating virtually? You can complete your run or walk anytime during the week of May 16–23, wherever it works best for you! pericarditisalliance.org/events/
1.7K
Cardiol Therapeutics Inc.
@CardiolRx
May 7
Very informative paper from the great team of our MAVERIC trial collaborators at the @ClevelandClinic!
Allan L. Klein
@AllanLKleinMD1
May 6
Important article how to use multimodality imaging for pericarditis. Congratulations to our pericardial team
540
Cardiol Therapeutics Inc.
@CardiolRx
May 7
Today we announced the results from our Phase II MAvERIC study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association (@JAHA_AHA). #JAHA #ClinicalTrials #CardiolRx
Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the...
From cardiolrx.com
6K
Cardiol Therapeutics Inc.
@CardiolRx
May 7
The peer-reviewed findings demonstrate rapid and sustained reductions in pericarditis pain and inflammation, a substantial reduction in pericarditis episodes per year, and a favorable safety profile in patients with high baseline disease burden.
265
Cardiol Therapeutics Inc.
@CardiolRx
May 7
These results support our ongoing Phase III MAVERIC trial, evaluating CardiolRx™ for the prevention of recurrent pericarditis. Enrollment has surpassed 75%, with full enrollment anticipated in the next few months. We’ll share the link to the full publication once it is
174
Cardiol Therapeutics Inc.
@CardiolRx
May 5
HFpEF now accounts for >50% of all heart failure cases — and most existing therapies were built for a different disease. It will affect nearly one in 10 people by the age of 45. In Canada, it is one of the leading causes of hospitalization for people over 65. The answer lies
Why the Most Common Form of Heart Failure Is Also the Hardest to Treat
From cardiolrx.com
197
Cardiol Therapeutics Inc.
@CardiolRx
May 4
This week is Heart Failure Awareness Week in Canada. Over 850,000 Canadians are living with heart failure, with more than 100,000 new diagnoses expected this year. 1-in-4 people will develop HF in their lifetime. At Cardiol, we’re advancing anti-inflammatory and anti-fibrotic
387